Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:HEATR2-ZNRF3

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: HEATR2-ZNRF3
	FusionPDB ID: 35956
	FusionGDB2.0 ID: 35956
		Hgene	Tgene
	Gene symbol	HEATR2	ZNRF3
	Gene ID	54919	84133
	Gene name	dynein axonemal assembly factor 5	zinc and ring finger 3
	Synonyms	CILD18\|HEATR2	BK747E2.3\|RNF203
	Cytomap	7p22.3	22q12.1
	Type of gene	protein-coding	protein-coding
	Description	dynein assembly factor 5, axonemalHEAT repeat containing 2HEAT repeat-containing protein 2	E3 ubiquitin-protein ligase ZNRF3CTA-292E10.6RING finger protein 203RING-type E3 ubiquitin transferase ZNRF3novel C3HC4 type Zinc finger (ring finger)zinc/RING finger protein 3
	Modification date	20200313	20200313
	UniProtAcc	.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000438961, ENST00000297440, ENST00000313147, ENST00000403952,	ENST00000332811, ENST00000402174, ENST00000406323, ENST00000544604,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	6 X 2 X 5=60	16 X 21 X 8=2688
	# samples	6	21
	** MAII score	log2(6/60*10)=0	log2(21/2688*10)=-3.67807190511264 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: HEATR2 [Title/Abstract] AND ZNRF3 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: HEATR2 [Title/Abstract] AND ZNRF3 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	HEATR2(769484)-ZNRF3(29442704), # samples:1
Anticipated loss of major functional domain due to fusion event.	HEATR2-ZNRF3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. HEATR2-ZNRF3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	ZNRF3	GO:0016567	protein ubiquitination	22575959

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:769484/chr22:29442704)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across HEATR2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across ZNRF3 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000297440	HEATR2	chr7	769484	-	ENST00000544604	ZNRF3	chr22	29442704	+	6732	800	20	2866	948
ENST00000297440	HEATR2	chr7	769484	-	ENST00000332811	ZNRF3	chr22	29442704	+	6732	800	20	2866	948
ENST00000297440	HEATR2	chr7	769484	-	ENST00000402174	ZNRF3	chr22	29442704	+	2930	800	20	2866	948
ENST00000297440	HEATR2	chr7	769484	-	ENST00000406323	ZNRF3	chr22	29442704	+	3210	800	20	2866	948
ENST00000313147	HEATR2	chr7	769484	-	ENST00000544604	ZNRF3	chr22	29442704	+	6732	800	20	2866	948
ENST00000313147	HEATR2	chr7	769484	-	ENST00000332811	ZNRF3	chr22	29442704	+	6732	800	20	2866	948
ENST00000313147	HEATR2	chr7	769484	-	ENST00000402174	ZNRF3	chr22	29442704	+	2930	800	20	2866	948
ENST00000313147	HEATR2	chr7	769484	-	ENST00000406323	ZNRF3	chr22	29442704	+	3210	800	20	2866	948

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000297440	ENST00000544604	HEATR2	chr7	769484	-	ZNRF3	chr22	29442704	+	0.003168671	0.99683136
ENST00000297440	ENST00000332811	HEATR2	chr7	769484	-	ZNRF3	chr22	29442704	+	0.003168671	0.99683136
ENST00000297440	ENST00000402174	HEATR2	chr7	769484	-	ZNRF3	chr22	29442704	+	0.027311513	0.97268856
ENST00000297440	ENST00000406323	HEATR2	chr7	769484	-	ZNRF3	chr22	29442704	+	0.016151177	0.9838488
ENST00000313147	ENST00000544604	HEATR2	chr7	769484	-	ZNRF3	chr22	29442704	+	0.003168671	0.99683136
ENST00000313147	ENST00000332811	HEATR2	chr7	769484	-	ZNRF3	chr22	29442704	+	0.003168671	0.99683136
ENST00000313147	ENST00000402174	HEATR2	chr7	769484	-	ZNRF3	chr22	29442704	+	0.027311513	0.97268856
ENST00000313147	ENST00000406323	HEATR2	chr7	769484	-	ZNRF3	chr22	29442704	+	0.016151177	0.9838488

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for HEATR2-ZNRF3

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
HEATR2	chr7	769484	ZNRF3	chr22	29442704	800	259	LSHFAQRLFDDVPQNSMNRLAVQALE

Top

Potential FusionNeoAntigen Information of HEATR2-ZNRF3 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

HEATR2-ZNRF3_769484_29442704.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A66:01	DVPQNSMNR	0.9964	0.638	10	19
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A26:03	DVPQNSMNR	0.9868	0.6339	10	19
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B35:03	VPQNSMNRL	0.8881	0.8466	11	20
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B35:02	VPQNSMNRL	0.683	0.7632	11	20
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B35:04	VPQNSMNRL	0.683	0.7632	11	20
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B39:13	FDDVPQNSM	0.3739	0.8739	8	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B15:01	RLFDDVPQNSM	0.9999	0.9345	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B15:25	RLFDDVPQNSM	0.9991	0.9422	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:17	RLFDDVPQNSM	0.9982	0.5047	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:13	RLFDDVPQNSM	0.998	0.6746	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:27	RLFDDVPQNSM	0.998	0.5016	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:16	RLFDDVPQNSM	0.9977	0.5858	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:04	RLFDDVPQNSM	0.9975	0.6782	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:11	RLFDDVPQNSM	0.9975	0.5626	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:67	RLFDDVPQNSM	0.9974	0.5279	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:30	RLFDDVPQNSM	0.9974	0.5279	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:60	RLFDDVPQNSM	0.9974	0.5099	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:24	RLFDDVPQNSM	0.9974	0.5279	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:21	RLFDDVPQNSM	0.9968	0.6394	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:35	RLFDDVPQNSM	0.9915	0.5404	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:38	RLFDDVPQNSM	0.987	0.7053	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B48:01	RLFDDVPQNSM	0.9709	0.612	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:29	RLFDDVPQNSM	0.9002	0.5281	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B13:01	RLFDDVPQNSM	0.8841	0.9638	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:20	RLFDDVPQNSM	0.8629	0.5384	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C05:09	FDDVPQNSM	0.9997	0.9042	8	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C04:10	FDDVPQNSM	0.9996	0.6806	8	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C04:07	FDDVPQNSM	0.9996	0.6846	8	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C08:15	FDDVPQNSM	0.9993	0.9355	8	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B07:12	VPQNSMNRL	0.8758	0.5977	11	20
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C08:03	FDDVPQNSM	0.7933	0.9202	8	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B35:12	VPQNSMNRL	0.683	0.7632	11	20
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B39:08	FDDVPQNSM	0.6661	0.6506	8	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B39:09	FDDVPQNSM	0.6335	0.5505	8	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B39:10	VPQNSMNRL	0.4248	0.8778	11	20
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C05:09	LFDDVPQNSM	1	0.9537	7	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C08:15	LFDDVPQNSM	0.9999	0.9674	7	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C04:07	LFDDVPQNSM	0.9999	0.6872	7	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C04:10	LFDDVPQNSM	0.9999	0.6901	7	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C04:14	LFDDVPQNSM	0.9859	0.7858	7	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B15:07	RLFDDVPQNSM	0.9999	0.8594	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B15:04	RLFDDVPQNSM	0.9999	0.9465	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C04:10	LFDDVPQNSMN	0.9999	0.7167	7	18
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C04:10	RLFDDVPQNSM	0.9999	0.8438	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C04:07	RLFDDVPQNSM	0.9999	0.8293	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:01	RLFDDVPQNSM	0.9974	0.5279	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B15:05	RLFDDVPQNSM	0.9912	0.938	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C05:01	FDDVPQNSM	0.9997	0.9042	8	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C04:03	FDDVPQNSM	0.9996	0.745	8	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C04:01	FDDVPQNSM	0.9996	0.6846	8	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C08:02	FDDVPQNSM	0.9993	0.9355	8	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C18:01	FDDVPQNSM	0.9993	0.712	8	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B35:13	VPQNSMNRL	0.8941	0.8492	11	20
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C08:01	FDDVPQNSM	0.7933	0.9202	8	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B35:09	VPQNSMNRL	0.683	0.7632	11	20
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B39:11	FDDVPQNSM	0.6759	0.6045	8	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B39:02	FDDVPQNSM	0.5048	0.874	8	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B67:01	VPQNSMNRL	0.4934	0.6343	11	20
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C05:01	LFDDVPQNSM	1	0.9537	7	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C04:03	LFDDVPQNSM	1	0.753	7	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C08:02	LFDDVPQNSM	0.9999	0.9674	7	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C04:01	LFDDVPQNSM	0.9999	0.6872	7	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C18:01	LFDDVPQNSM	0.9998	0.7252	7	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C04:04	LFDDVPQNSM	0.9822	0.9132	7	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C07:04	LFDDVPQNSM	0.9763	0.913	7	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B08:12	LFDDVPQNSM	0.5403	0.6261	7	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-C04:01	RLFDDVPQNSM	0.9999	0.8293	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B15:33	RLFDDVPQNSM	0.9999	0.9345	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B15:34	RLFDDVPQNSM	0.9999	0.9345	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B15:125	RLFDDVPQNSM	0.9999	0.9345	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B15:35	RLFDDVPQNSM	0.9999	0.9489	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B15:50	RLFDDVPQNSM	0.9999	0.9431	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B15:73	RLFDDVPQNSM	0.9994	0.973	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A32:01	RLFDDVPQNSM	0.9993	0.9626	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B15:30	RLFDDVPQNSM	0.9992	0.9719	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B15:39	RLFDDVPQNSM	0.9992	0.88	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:14	RLFDDVPQNSM	0.9972	0.5906	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:03	RLFDDVPQNSM	0.9968	0.6564	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-A02:06	RLFDDVPQNSM	0.9968	0.6394	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B15:20	RLFDDVPQNSM	0.9911	0.9573	6	17
HEATR2-ZNRF3	chr7	769484	chr22	29442704	800	HLA-B40:21	RLFDDVPQNSM	0.8876	0.6042	6	17

Top

Potential FusionNeoAntigen Information of HEATR2-ZNRF3 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of HEATR2-ZNRF3

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
8004	RLFDDVPQNSMNRL	HEATR2	ZNRF3	chr7	769484	chr22	29442704	800

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of HEATR2-ZNRF3

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	8004	RLFDDVPQNSMNRL	-6.11479	-7.15009
HLA-B14:02	3BVN	8004	RLFDDVPQNSMNRL	-4.76706	-4.88046
HLA-B52:01	3W39	8004	RLFDDVPQNSMNRL	-6.87405	-6.98745
HLA-B52:01	3W39	8004	RLFDDVPQNSMNRL	-5.3619	-6.3972
HLA-A11:01	4UQ2	8004	RLFDDVPQNSMNRL	-9.79836	-9.91176
HLA-A24:02	5HGA	8004	RLFDDVPQNSMNRL	-8.83847	-8.95187
HLA-A24:02	5HGA	8004	RLFDDVPQNSMNRL	-8.05027	-9.08557
HLA-B44:05	3DX8	8004	RLFDDVPQNSMNRL	-7.51915	-7.63255
HLA-B44:05	3DX8	8004	RLFDDVPQNSMNRL	-4.45384	-5.48914
HLA-A02:01	6TDR	8004	RLFDDVPQNSMNRL	-2.8902	-3.9255

Top

Vaccine Design for the FusionNeoAntigens of HEATR2-ZNRF3

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
HEATR2-ZNRF3	chr7	769484	chr22	29442704	10	19	DVPQNSMNR	GTCCCGCAGAATTCCATGAACAGGCTG
HEATR2-ZNRF3	chr7	769484	chr22	29442704	11	20	VPQNSMNRL	CCGCAGAATTCCATGAACAGGCTGGCT
HEATR2-ZNRF3	chr7	769484	chr22	29442704	6	17	RLFDDVPQNSM	CTGTTTGATGACGTCCCGCAGAATTCCATGAAC
HEATR2-ZNRF3	chr7	769484	chr22	29442704	7	17	LFDDVPQNSM	TTTGATGACGTCCCGCAGAATTCCATGAAC
HEATR2-ZNRF3	chr7	769484	chr22	29442704	7	18	LFDDVPQNSMN	TTTGATGACGTCCCGCAGAATTCCATGAACAGG
HEATR2-ZNRF3	chr7	769484	chr22	29442704	8	17	FDDVPQNSM	GATGACGTCCCGCAGAATTCCATGAAC

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of HEATR2-ZNRF3

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
BLCA	HEATR2-ZNRF3	chr7	769484	ENST00000297440	chr22	29442704	ENST00000332811	TCGA-FD-A3B6-01A

Top

Potential target of CAR-T therapy development for HEATR2-ZNRF3

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

ZNRF3

chr7:769484

chr22:29442704

ENST00000332811

220_240

837.0

Transmembrane

Helical

Tgene

ZNRF3

chr7:769484

chr22:29442704

ENST00000402174

220_240

837.0

Transmembrane

Helical

Tgene

ZNRF3

chr7:769484

chr22:29442704

ENST00000406323

220_240

837.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to HEATR2-ZNRF3

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to HEATR2-ZNRF3

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)